Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2018 08:19 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic Syndrome

CORAL GABLES, Fla., March 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
March 14, 2018 16:13 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update

--Firdapse® NDA to be Resubmitted Before the End of this Quarter --Significant Progress with MuSK-MG Regulatory and Clinical Program --$84M Year-End Cash and Investments --Company to Host Quarterly...
March 12, 2018 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast

CORAL GABLES, Fla., March 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
March 08, 2018 08:04 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results Conference Call and Webcast on Thursday, March 15th, 2018

CORAL GABLES, Fla., March 08, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
February 28, 2018 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018

CORAL GABLES, Fla., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for...
February 12, 2018 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse®

Positive meeting with the FDA about the resubmission of an NDA for FirdapseResubmission of NDA for Firdapse on schedule for end of the first quarter CORAL GABLES, Fla., Feb. 12, 2018 (GLOBE...
February 07, 2018 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Present at Two Upcoming Investor Conferences

CORAL GABLES, Fla., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
November 30, 2017 14:07 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. Announces Closing of Previously Announced Public Offering

CORAL GABLES, Fla., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX) today reported that it has closed its previously announced public offering of shares of its common...
November 27, 2017 16:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

CORAL GABLES, Fla., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX) announced today that it has commenced an underwritten public offering of 11 million shares of its...
November 27, 2017 06:30 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Positive Top-Line Results from Second Phase 3 Clinical Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome

-- Treatment with Firdapse Achieved Statistical Significance for Co-Primary Endpoints and Secondary Endpoint -- -- Positive Results to Support Planned NDA Submission in the First Quarter of 2018 -- ...